XML 102 R125.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Segment Information (Details) (USD $) In Thousands, unless otherwise specified | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011
Revenue by product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product, net | $ 1,607,100 | [1],[2] | $ 1,453,600 | $ 1,385,900 | [3] | $ 1,095,800 | [4] | $ 1,074,700 | [5] | $ 1,039,100 | $ 1,076,800 | [6] | $ 975,400 | $ 5,542,331 | $ 4,166,074 | $ 3,836,117
U.S |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue by product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,581,000 | 2,176,800 | 1,954,800
Rest of world |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue by product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,961,300 | 1,989,300 | 1,881,300
AVONEX |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue by product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,005,500 | 2,913,100 | 2,686,600
AVONEX | U.S |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue by product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,902,400 | 1,793,700 | 1,628,300
AVONEX | Rest of world |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue by product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,103,100 | 1,119,400 | 1,058,300
TYSABRI |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue by product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,526,500 | 1,135,900 | 1,079,500
TYSABRI | U.S |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue by product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  |  |  |  |  |  | 814,200 | 383,100 | 326,500
TYSABRI | Rest of world |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue by product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  |  |  |  |  |  | 712,300 | 752,800 | 753,000
TECFIDERA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue by product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  |  |  |  |  |  | 876,100 | 0 | 0
TECFIDERA | U.S |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue by product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  |  |  |  |  |  | 864,400 | 0 | 0
TECFIDERA | Rest of world |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue by product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  |  |  |  |  |  | 11,700 | 0 | 0
Other products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue by product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  |  |  |  |  |  | 134,200 | 117,100 | 70,000
Other products | U.S |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue by product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0
Other products | Rest of world |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue by product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product, net |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 134,200 | $ 117,100 | $ 70,000
[1] | Net income and net income attributable to Biogen Idec Inc. for the first quarter of 2012 includes a charge to research and development expense of $29.0 million related to an upfront payment made in connection with our development agreement entered into with Isis.
[2] | Net income and net income attributable to Biogen Idec Inc., for the third quarter of 2013, includes a charge to research and development expense of $75.0 million related to an upfront payment made in connection with our collaboration agreement entered into with Isis.
[3] | Product revenues and total revenues for the second, third and fourth quarters of 2013 includes 100% of net revenues related to sales of TYSABRI as a result of our acquisition of TYSABRI rights from Elan on April 2, 2013 and net revenues related to sales of TECFIDERA, our new oral first-line treatment for people with relapsing forms of multiple sclerosis (MS), which was approved by the FDA in March 2013 and commenced commercial sales in April 2013.
[4] | Our share of revenues from unconsolidated joint business reflects a charge of $41.5 million for damages and interest awarded to Hoechst in Genentech's arbitration with Hoechst for RITUXAN.
[5] | Net income and net income attributable to Biogen Idec Inc. for the fourth quarter of 2012 includes the correction of an error that had accumulated over several prior years in our deferred tax accounting for capitalized interest which resulted in an expense of $29.0 million.
[6] | Net income and net income attributable to Biogen Idec Inc. for the fourth quarter of 2012 includes a charge to research and development expense of $30.0 million related to an upfront payment made in connection with our development agreement entered into with Isis.

X
- Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_SalesRevenueGoodsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_SalesRevenueGoodsNetAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration